New drug duo aims to outsmart Platinum-Resistant ovarian cancer

NCT ID NCT05538091

Recruiting now Disease control Sponsor: Ronald Buckanovich Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of two drugs—vismodegib and atezolizumab—in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the combination is safe and can shrink tumors. About 48 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vismodegib and atezolizumab
What this could lead to: If this combination works, it could offer a new treatment option for patients with ovarian cancer that has stopped responding to platinum-based chemotherapy.
What could go wrong: This is an early phase 2 trial with only 48 participants, so results may not apply to everyone. The drugs can cause side effects like fatigue, nausea, and immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEDGEHOG INHIBITOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma ovarian carcinoma primary peritoneal carcinoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEDGEHOG INHIBITOR PARP INHIBITOR PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Locations

UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.